Ragweed Allergy - Pipeline Review, H2 2014

Published: Nov, 2014 | Pages: 45 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Ragweed Allergy - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Ragweed Allergy - Pipeline Review, H2 2014', provides an overview of the Ragweed Allergy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ragweed Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ragweed Allergy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Ragweed Allergy
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Ragweed Allergy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Ragweed Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Ragweed Allergy pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Ragweed Allergy
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Ragweed Allergy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Ragweed Allergy Overview 6
Therapeutics Development 7
Pipeline Products for Ragweed Allergy - Overview 7
Pipeline Products for Ragweed Allergy - Comparative Analysis 8
Ragweed Allergy - Therapeutics under Development by Companies 9
Ragweed Allergy - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Unknown Stage Products 13
Ragweed Allergy - Products under Development by Companies 14
Ragweed Allergy - Companies Involved in Therapeutics Development 15
Allergy Therapeutics plc 15
Anergis SA 16
Biomay AG 17
Circassia Pharmaceuticals plc 18
Immunomic Therapeutics, Inc. 19
Stallergenes S.A. 20
Ragweed Allergy - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
AllerR - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Drug for Ragweed Pollen Allergy - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Multi-LAMP-Vax - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
PL-101 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Pollinex Ragweed - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Ragweed Hypoallergenic Vaccine - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Ragweed-SPIRE - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Subunit Vaccine for Ragweed Allergy - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Ragweed Allergy - Recent Pipeline Updates 37
Ragweed Allergy - Dormant Projects 39
Ragweed Allergy - Discontinued Products 40
Ragweed Allergy - Product Development Milestones 41
Featured News & Press Releases 41
Feb 21, 2013: Anergis To Present Preclinical Data On Ragweed Allergy Vaccine Candidate AllerR At AAAAI 2013 Annual Meeting 41
Jun 14, 2012: Anergis Reaches Several Preclinical Development Milestones With Ragweed Pollen Vaccine 41
Mar 07, 2012: Circassia's Ragweed Allergy Therapy Achieves Positive Phase II Clinical Results 42
Jan 19, 2012: Circassia Receives European Patent For Its Ragweed Allergy T-Cell Vaccine 43
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 45
Disclaimer 45

List of Tables
Number of Products under Development for Ragweed Allergy, H2 2014 7
Number of Products under Development for Ragweed Allergy - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Late Stage Development, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Comparative Analysis by Unknown Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Ragweed Allergy - Pipeline by Allergy Therapeutics plc, H2 2014 15
Ragweed Allergy - Pipeline by Anergis SA, H2 2014 16
Ragweed Allergy - Pipeline by Biomay AG, H2 2014 17
Ragweed Allergy - Pipeline by Circassia Pharmaceuticals plc, H2 2014 18
Ragweed Allergy - Pipeline by Immunomic Therapeutics, Inc., H2 2014 19
Ragweed Allergy - Pipeline by Stallergenes S.A., H2 2014 20
Assessment by Monotherapy Products, H2 2014 21
Number of Products by Stage and Target, H2 2014 22
Number of Products by Stage and Route of Administration, H2 2014 24
Number of Products by Stage and Molecule Type, H2 2014 26
Ragweed Allergy Therapeutics - Recent Pipeline Updates, H2 2014 37
Ragweed Allergy - Dormant Projects, H2 2014 39
Ragweed Allergy - Discontinued Products, H2 2014 40